Neurofibromatosis type 1 as a model system to study molecular mechanisms of autism spectrum disorder symptoms

Prog Brain Res. 2018:241:37-62. doi: 10.1016/bs.pbr.2018.09.014. Epub 2018 Oct 25.

Abstract

Neurofibromatosis type 1 (NF1) is monogenic neurodevelopmental disorder caused by mutation of NF1 gene, which leads to increased susceptibility to various tumors formations. Additionally, majority of patients with NF1 are experience high incidence of cognitive deficits. Particularly, we review the growing number of reports demonstrated a higher incidence of autism spectrum disorder (ASD) in individuals with NF1. In this review we also discuss face validity of preclinical Nf1 mouse models. Then we describe discoveries from these animal models that have uncovered the deficiencies in the regulation of Ras and other intracellular pathways as critical mechanisms underlying the Nf1 cognitive problems. We also summarize and interpret recent preclinical and clinical studies that point toward potential pharmacological therapies for NF1 patients.

Keywords: Autism spectrum disorders; Behavior; Cognition; Mouse models; Neurofibromatosis type 1; PAK inhibitors.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Animals
  • Autism Spectrum Disorder* / drug therapy
  • Autism Spectrum Disorder* / genetics
  • Autism Spectrum Disorder* / metabolism
  • Autism Spectrum Disorder* / physiopathology
  • Cognitive Dysfunction* / drug therapy
  • Cognitive Dysfunction* / genetics
  • Cognitive Dysfunction* / metabolism
  • Cognitive Dysfunction* / physiopathology
  • Disease Models, Animal*
  • GABA Antagonists / pharmacology*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*
  • Mice
  • Neurofibromatosis 1* / drug therapy
  • Neurofibromatosis 1* / genetics
  • Neurofibromatosis 1* / metabolism
  • Neurofibromatosis 1* / physiopathology
  • Protein Kinase Inhibitors / pharmacology*

Substances

  • GABA Antagonists
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Protein Kinase Inhibitors